Patients with high PD-L1 expression, defined as ≥50% of tumor cells or ≥10% of tumor-infiltrating immune cells assessed by the SP142 immunohistochemistry (IHC) assay (Ventana), showed a median OS of 20.2 months with atezolizumab monotherapy versus 13.1 months with platinum-based chemotherapy (hazard ratio (HR), 0.59; 95% confidence interval (CI): 0.40, 0.89; P = 0.0106)18. The gene discussed is CD274; the disease is neoplasm.